2nd Department of Propaedeutic Surgery, National and Kapodistrian University of Athens, Medical School, Athens, Greece.
Department of Anatomy, National and Kapodistrian University of Athens, Medical School, Athens, Greece.
Curr Pharm Des. 2021;27(18):2199-2208. doi: 10.2174/1381612826666201211112234.
BACKGROUND/AIM: Papillary Thyroid Cancer (PTC) is the most common type of endocrine malignancy. Although PTC has an excellent prognosis, the recurrent or metastatic disease could affect patients' survival. Recent studies show that Histone Deacetylase Inhibitors (HDACIs) might be promising anticancer agents against PTC. The aim of this review is to evaluate the role of HDACIs as an additional modality in PTC treatment and to depict the latest trends of current research on this field.
This literature review was performed using the MEDLINE database. The search strategy included terms: "thyroid cancer", "papillary", "HDAC", "histone", and "deacetylase".
Agents, such as Suberoyl Anilide Hydroxamic Acid, Trichostatin A, Valproic Acid, Sodium butyrate, Panobinostat, Belinostat, Romidepsin, CUDC907 and N-Hydroxy-7-(2-naphthylthio)-Hepanomide have shown promising anti-cancer effects on PTC cell lines but fail to trigger a major response in clinical trials.
HDACIs have no significant effect as monotherapy against PTC, but further research needs to be conducted in order to investigate their potential effect when used as an additional modality.
背景/目的：甲状腺癌（PTC）是最常见的内分泌恶性肿瘤。尽管 PTC 的预后良好，但复发或转移性疾病仍可能影响患者的生存。最近的研究表明，组蛋白去乙酰化酶抑制剂（HDACIs）可能是治疗 PTC 的有前途的抗癌药物。本综述旨在评估 HDACIs 作为 PTC 治疗的附加方式的作用，并描述该领域当前研究的最新趋势。
本文献综述使用 MEDLINE 数据库进行。搜索策略包括以下术语：“甲状腺癌”、“乳头状”、“HDAC”、“组蛋白”和“去乙酰化酶”。
几种药物，如琥珀酰亚胺基羟肟酸、曲古抑菌素 A、丙戊酸、丁酸钠、帕比司他、贝利司他、罗米地辛、CUDC907 和 N-羟基-7-(2-萘基硫代)-庚酰胺，对 PTC 细胞系显示出有希望的抗癌作用，但在临床试验中未能引起重大反应。
HDACIs 作为单一疗法对 PTC 没有显著疗效，但需要进一步研究，以探讨其作为附加方式的潜在效果。
